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Abstract The kinetics of amyloid plaque formation and
growth as one of the characteristic hallmarks of Alzhei-
mer’s disease (AD) are fundamental issues in AD research.
Especially the question how fast amyloid plaques grow
to their ﬁnal size after they are born remains controversial.
By long-term two-photon in vivo imaging we monitored
individual methoxy-X04-stained amyloid plaques over
6 weeks in 12 and 18 months old Tg2576 mice. We found
that in 12 months old mice, newly appearing amyloid
plaques were initially small in volume and subsequently
grew over time. The growth rate of plaques was inversely
proportional to their volume; thus amyloid plaques that
were already present at the ﬁrst imaging time point grew
over time but slower compared to new plaques. Addition-
ally, we analyzed 18 months old Tg2576 mice in which we
neither found newly appearing plaques nor a signiﬁcant
growth of pre-existing plaques over 6 weeks of imaging. In
conclusion, newly appearing amyloid plaques are initially
small in size but grow over time until plaque growth can
not be detected anymore in aged mice. These results
suggest that drugs that target plaque formation should be
most effective early in the disease, when plaques are
growing.
Keywords Alzheimer’s disease  Amyloid plaque 
Ab, plaque growth  Tg2576  Two-photon  In vivo 
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Introduction
Amyloid plaques represent one of the major hallmarks of
Alzheimer’s disease (AD) pathology. They are comprised
of ﬁbrillar aggregates of the amyloid-b-peptide which has
been shown to have synaptotoxic effects [10, 17, 18, 23]. In
AD patients as well as in animal models synapse loss is
most prominent in close proximity to amyloid plaque
deposits which indicates a link between amyloid plaques
and synaptotoxicity [7, 14, 15, 19–21]. Therefore, eluci-
dating the process of amyloid plaque formation and growth
may reveal important targets for therapeutic interventions
to stop the progression of synapse loss and consequently
cognitive decline in AD.
In vitro studies of plaque formation established a model
in which a seed of ﬁbrillar Ab is formed ﬁrst and plaques
grow subsequently around these seeds in a time- and
concentration-dependent manner [4, 11]. These ﬁndings
were corroborated by in vivo imaging studies of AD
transgenic (APP/PS1) mice, which reported a change in
size of a subset of plaques [2] or a gradual growth of almost
all plaques, which was faster in smaller plaques and
younger animals [24]. These ﬁndings, however, are con-
trasted by different studies, which reported that Ab plaques
appeared rapidly in both APP/PS1 and Tg2576 transgenic
mice [16] and that these were relatively stable over time in
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DOI 10.1007/s00401-010-0787-6Tg2576 transgenic mice [3]. The apparent discrepancies of
the in vivo studies may be attributed to a different prepa-
ration of the cranial window (e.g., thinned skull vs. open
skull preparations), the age of the mice, or different disease
models (e.g., APP/PS1 or Tg2576). In order to reconcile
these ﬁndings, we studied the appearance of Ab plaques in
detail. We followed plaque formation in 12 and 18 months
old Tg2576 mice by measuring the volume, as well as area,
over a period of 6 weeks. While we used an open skull
preparation, we started our imaging protocol 3 weeks after
surgery, so that possible artifacts from inﬂammatory
reactions [8] were minimized.
Using this approach, we found that plaques appeared
and increased in volume in 12 months old, but not in
18 months old mice. Nascent plaques were initially small
in volume and grew over time. Pre-existing plaques, in
contrast, had a larger volume and grew slower compared to
newly formed ones. These ﬁndings demonstrate that Ab
plaques grow in a size-dependent manner in young
(12 months) mice, while no growth was observed in older
(18 months) mice.
Materials and methods
Transgenic mice
Heterozygous Tg2576 [9] mice (B6;SJL-Tg(APPSWE)
2576Kha from Taconic, Cologne, Germany) were crossed
with heterozygous YFP-H [5] mice (B6.Cg-Tg(Thy1-
YFPH)2Jrs/J) from The Jackson Laboratory, Bar Harbor,
USA) expressing yellow ﬂuorescent protein (YFP) in a
subset of cortical neurons. YFP-labeled neurons served as a
counterstaining to ﬁnd the same imaging positions over and
over again in subsequent time points. Mice were of both
sexes and were group housed under pathogen-free condi-
tions until surgery, after which they were singly housed.
All procedures were performed in accordance with an
animal protocol approved by the University of Munich
and the Government of Upper Bavaria (55.2-1.54-2531-
110-06).
Open-skull surgery
A cranial window over the right cortical hemisphere was
surgically implanted as previously described [1, 6, 8]. The
mice were anesthetized with an intraperitoneal injection
of ketamine/xylazine (0.13/0.01 mg/g body weight).
Additionally, dexamethasone (0.02 ml at 4 mg/ml) was
intraperitoneally administered immediately before surgery
(Holtmaat et al. 2005). A circular piece of the skull (4 mm
in diameter) over the right somatosensory cortex (centered
over the parietal bone, approx. 5.5 mm caudal from the
bregma and 5.5 mm lateral of the midline) was removed
using a dental drill (Schick-Technikmaster C1; Pluradent;
Offenbach, Germany). Immediately, a round coverslip
(5 mm diameter) was glued to the skull using dental acrylic
(Cyano-Veneer fast; Heinrich Schein Dental Depot,
Munich, Germany) to close the craniotomy. A small metal
bar, containing a hole for a screw, was glued next to the
coverslip to allow repositioning of the mouse during sub-
sequent imaging sessions. After surgery, mice received a
subcutaneous analgesic dose of carprophen (Rimadyl;
Pﬁzer, New York, USA) for 3 days (5 mg/kg). Imaging
began following a 21 day rest period after surgery.
Long-term two-photon in vivo imaging
Long-term two-photon imaging was performed as previ-
ously described [1, 6]. Less than 50 mW laser power was
delivered to the tissue to avoid laser-induced phototoxicity.
For amyloid plaque staining, methoxy-X04 [13] was intra-
peritoneally injected 24 h before every imaging session.
Initially, we administered doses of 2.4 mg/kg. However, in
an attempt to reduce methoxy-X04 usage, we changed the
dosing regimen to an initial loading dose of 2.0 mg/kg
before the ﬁrst imaging session and subsequent weekly
maintenance doses of 0.4 mg/kg, which did not affect the
signal-to-noise ratio (data not shown). Furthermore, we
found no signiﬁcant difference in plaque growth between
these two dosing regimens (Supplementary Fig. S1a),
therefore we pooled the data for all further analyses. To
determine whether repeatedadministration of methoxy-X04
increased the apparent volume of plaques by increasing the
brightness, we correlated plaque volumes with the mean
intensity of the ﬂuorescence values of all voxels in a plaque
(Supplementary Fig. S1b). The correlation between plaque
volume and intensity was weak (R
2 = 0.25) compared to
data obtained by imaging ﬂuorescent beads with varying
laser intensities to simulate increasing brightness
(R
2 = 0.71; data not shown). Considering that no plaque
growth was observed in older animals despite the same
dosing scheme and that comparably little plaque growth
was observed with daily administration of methoxy-X04
(Supplementary Fig. S2), changes in plaque volumes cannot
be attributed to increased brightness due to methoxy-X04
accumulation.
YFP and methoxy-X04 were excited by a Ti:Sa laser
(MaiTai, Spectra-Physics, Darmstadt, Germany) at 880 and
750 nm and the emission was collected from 527 to 582 nm
and 460 to 500 nm, respectively (LSM 5MP, Zeiss, Jena,
Germany). A Zeiss 209 water-immersion objective (1.0
NA) was used to acquire image stacks of 425 9 425 9
300 lm
3 with 3 lm z-resolution and 1,024 9 1,024 pixels
per image frame (0.41 lm/pixel). In subsequent imaging
sessions, previously imaged volumes were identiﬁed by
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123eye, based on the positions of blood vessels, neuronal cell
bodies and processes, as well as plaques. This allowed the
precise alignment of the same imaging volume over a per-
iod of 6 weeks. The laser intensity was adjusted to keep the
emitted YFP ﬂuorescence stable.
Image processing and data analysis
The 3D images were deconvolved (AutoDeblur, Version
x2.0.1, Media Cybernetics, Bethesda, USA) and contrast-
normalized (i.e., based on the average and standard devi-
ation of intensities of 3D stacks; Imaris 6.2.1, Bitplane,
Zurich, Switzerland). For 3D analysis, we used surface
rendering by Imaris software which also calculated the
volume of individual plaques over time period. The 2D
analysis was performed in maximum intensity projections
applying a threshold of mean intensity ? twice standard
deviation of a representative background region. The vol-
ume growth of individual plaques was quantiﬁed as the
slope of a linear ﬁt of the volumes measured at each time
point. We used repeated measures ANOVA and Student’s
t-test to test signiﬁcance. All data are presented as
mean ± SD, and 95% conﬁdence intervals (95% CI) are
given where appropriate.
Results
We imaged 83 individual amyloid plaques in 12 months
old Tg2576 mice [9]( n = 8) for up to 6 weeks (Fig. 1a).
Volumes of individual plaques were three-dimensionally
(3D) surface-rendered, quantiﬁed, and tracked over time
(Fig. 1b). To compare the growth of plaques of various
sizes, we normalized the volume of individual plaques to
their volume at the ﬁrst imaging session (week 0). In total,
we detected the appearance of 25 new plaques during the
imaging period of 6 weeks. Initially, these newborn pla-
ques had an average volume of 255 ± 231 lm
3 (95% CI,
159–350 lm
3; Fig. 2) and exhibited a signiﬁcant volume
increase of 2,015 ± 1,783% over 6 weeks based on a
linear regression (Fig. 3a–c; P\0.001, R
2 = 0.97). The
initial area of newborn plaques, as determined from the
maximum intensity projection, was 33.8 ± 21.6 lm
2 (95%
CI, 24.5–43.2 lm
2) and they exhibited a signiﬁcant area
increase of 591 ± 409% over 6 weeks based on a linear
regression (Fig. 3d; P\0.001, R
2 = 0.95). Plaques that
were not observed in their nascent stage, so called pre-
existing plaques (n = 58) had an initial average volume of
7,575 ± 15,599 lm
3 (95% CI, 3,473–11,676 lm
3; Fig. 2)
and an initial average area, as determined from the
Fig. 1 Long-term two-photon in vivo imaging of amyloid plaques.
a Schematic of a cranial window implanted over the somatosensory
cortex of a Tg2576 mouse that was crossed with YFP-H. A volume
rendered z-stack with perspective view (45) shows amyloid plaques
in blue (stained with methoxy-X04) and YFP-labeled dendrites in
green at week 0 which was the ﬁrst imaging time point. Amyloid
plaques were followed over 6 weeks with weekly imaging time points
illustrated as maximum intensity projections. b Illustration of the
image analysis with Imaris software. After the amyloid plaques in the
raw images were 3D surface rendered, the software automatically
calculated the plaque volume which was then color-coded. Major
ticks show 50 lm
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123maximum intensity projection, of 141.0 ± 262.1 lm
2
(95% CI, 73.3–208.7 lm
2). Both volume as well as area
was signiﬁcantly higher compared to newborn plaques
(P\0.001). These pre-existing plaques exhibited a
signiﬁcant linear volume increase of 426 ± 313% over
6 weeks (Fig. 4a–c, P\0.001, R
2 = 0.99), whereas the
area increased by 282 ± 123% over 6 weeks based on a
linear regression (Fig. 4d; P\0.001, R
2 = 0.97). Collec-
tively, all amyloid plaques analyzed in 12 months old
Tg2576 mice signiﬁcantly gained volume and area over
6 weeks (P\0.001). In contrast, we neither detected
newly appearing plaques, nor a signiﬁcant increase in
plaque volume in 18 months old Tg2576 mice over
6 weeks (Fig. 5; n = 126 plaques in three mice). At this
age, amyloid plaques had an average volume of 14,632 ±
27,811 lm
3 (95% CI, 9,729–19,536 lm
3; Fig. 2), which is
signiﬁcantly higher than at 12 months (Fig. 2, P\0.001).
We also determined the sphericity of the larger, pre-
existing plaques, which is deﬁned as the ratio of the surface
area of a sphere which has the same volume as the given
plaque to the surface area of the plaque [22]. On average,
the sphericity of n = 101 plaques was 0.86 ± 0.07
(95% CI, 0.84–0.87), which differed signiﬁcantly from 1
(i.e., a perfect sphere; Wilcoxon signed rank test,
P\0.0001). Finally, we quantiﬁed the growth of indi-
vidual plaques as the slope of a linear ﬁt of the normalized
volumes measured at each time point and plotted these
against the initial volumes of each respective plaque
(Fig. 6). This analysis shows a slight overlap in volumes of
newborn and pre-existing plaques (Fig. 6a). This is most
likely due to the sampling rate of plaque volumes (i.e.,
weekly), so that plaques labeled as ‘‘newborn’’ may have
existed for up to a week before we detected them for the
ﬁrst time. More importantly, however, we found that in
young (12 months) mice, plaque growth is directly related
to the volume of a plaque (Fig. 6a), whereas most plaques
in older (18 months) mice show very little, if any, growth
(Fig. 6b).
Discussion
We monitored the appearance and growth of Ab plaques in
Tg2576 mice by in vivo two-photon microscopy of animals
pretreated with methoxy-X04, which stains Ab plaques. As
a model, we used Tg2576 mice, which overexpress a
human APP transgene containing the Swedish FAD
mutation (K670N/M671L), and display the slowest amy-
loid pathology [9] of all the models analyzed by Meyer-
Luehmann et al. [16]. We reasoned that if we were able to
detect amyloid plaque growth in this model, then it should
also be detectable in other mouse models with a faster
amyloid pathology.
In summary, we showed that in the early stages of
amyloid pathology in Tg2576 mice, newborn plaques are
initially small in size and grow over time. These ﬁndings
are in contrast to the previous study by Meyer-Luehmann
et al. [16] which found that plaques appeared very rapidly
(within 24 h) and did not change signiﬁcantly in size
thereafter. One possible reason for the differing results
might be the fact that we primarily quantiﬁed volume,
rather than area. However, even when we quantiﬁed plaque
size as an area, that area steadily increased over 6 weeks
(Figs. 3d, 4d). Thus, quantiﬁcation of the plaques in three
dimensions does not account for the observed difference.
Another possibility is that open-skull surgery induces local
inﬂammation and gliosis in the ﬁrst weeks after surgery [8],
which may affect plaque growth [24]. Therefore, in con-
trast to Meyer-Luehmann et al. [16], we waited for 3 weeks
before imaging, so that possible inﬂammatory responses
could abate. Yet even when we started daily imaging
immediately after cranial window surgery, we were able to
Fig. 2 Distribution of amyloid plaque volumes. Distribution of
amyloid plaque volumes between individual newborn (n = 25) and
pre-existing plaques (n = 58) in 12 months old Tg2576 and pre-
existing plaques (n = 128) at 18 months of age. The red bars show
mean and 95% CI. ***P\0.001 (Kruskal–Wallis test with Dunn’s
post-hoc test)
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123measure plaque growth. Initial plaque volumes were
92.1 ± 64.5 lm
3 (95% CI, 60.0–124 lm
3; n = 18).
However, a signiﬁcant increase in plaque volume was only
detected if we monitored plaque sizes for more than
16 days (Supplementary Fig. S2). Thus, delayed imaging
3 weeks after surgery does not account for the observed
Fig. 3 Growth of newborn
amyloid plaques in 12 months
old Tg2576. a Maximum
intensity projections of a time
series of 3D images acquired
with two-photon in vivo
imaging in 12 months old
Tg2576 mice. A newborn
amyloid plaque (stained with
methoxy-X04) is displayed in
blue and YFP-labeled dendrites
in green. This newborn plaque
is not apparent at week 0 but
emerges at week 2. b In the
following weeks, the nascent
plaque considerably increased
in size indicated by color-coded
surface rendered objects. c The
diagram shows normalized
volumes of 25 individual
newborn plaques (grey lines)
based on the volume of ﬁrst
appearance. Week 0 is set as the
time-point of ﬁrst appearance.
Average plaque volumes (red
triangles), and linear regression
of average plaque volume
(red line) over 6 weeks are
displayed. d The diagram shows
normalized areas of 25
individual newborn plaques
(grey lines) based on the area of
ﬁrst appearance. Week 0 is set
as the time-point of ﬁrst
appearance. Average plaque
areas (red triangles), and linear
regression of average plaque
volume (red line) over 6 weeks
are displayed. Error bars
show standard deviation.
***P\0.001; Scale bars
show 10 lm
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123differences, either. We identiﬁed, however, two factors
which determined if plaque growth can be observed in
Tg2576 mice; ﬁrst, and most importantly, we found that
plaque growth can only be detected after a sufﬁciently long
observation period. We monitored plaques for six consec-
utive weeks and detected that a statistically signiﬁcant
change in plaque volume of newborn plaques was achieved
not earlier than 2 weeks after their ﬁrst appearance
(Fig. 3c), whereas a statistically signiﬁcant change in pla-
que volume of pre-existing plaques was achieved not
earlier than 4 weeks after the initial measurement (Fig. 4c).
Second, we also found that the age of the observed animals
Fig. 4 Growth of pre-existing
amyloid plaques in 12 months
old Tg2576. a Maximum
intensity projections of a time
series of 3D images acquired
with two-photon in vivo
imaging in 12 months old
Tg2576 mice. A pre-existing
amyloid plaque (stained with
methoxy-X04) is displayed in
blue and YFP-labeled dendrites
in green. This plaque is already
apparent at week 0. b In the
following weeks, the plaque
considerably increased in size
indicated by color-coded
surface rendered objects.
c The diagram shows
normalized volumes of 58
individual plaques (grey lines)
based on the volume at the ﬁrst
imaging time-point (week 0).
Average plaque volumes (red
triangles), and linear regression
of average plaque volume
(red line) over 6 weeks are
displayed. d The diagram shows
normalized areas of 58
individual plaques (grey lines)
based on the volume at the ﬁrst
imaging time-point (week 0).
Average plaque areas (red
triangles), and linear regression
of average plaque area (red line)
over 6 weeks are displayed.
Error bars show standard
deviation. *P\0.05,
**P\0.01, ***P\0.001;
Scale bars show 10 lm
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123plays an important role; we detected plaque growth in
12 months old mice, whereas 18 months old mice showed
no signiﬁcant overall growth of plaques (Figs. 5c, 6),
which was shown before by Christie et al. [3]. Glial
interaction with amyloid deposits has previously been
suggested as a possible explanation for this observation in
Fig. 5 Growth of pre-existing
amyloid plaques in 18 months
old Tg2576. a Maximum
intensity projections of a time
series of 3D images acquired
with two-photon in vivo
imaging in 18 months old
Tg2576 mice. A pre-existing
amyloid plaque (stained with
methoxy-X04) is displayed in
blue and YFP-labeled dendrites
in green. This plaque is already
apparent at week 0. b In the
following weeks, the plaque
does not increased in size
indicated by color-coded
surface rendered objects. c The
diagram shows normalized
volumes of 126 individual
plaques (grey lines) based on
the volume at the ﬁrst imaging
time-point (week 0). Average
plaque volumes (red triangles),
and linear regression of average
plaque volume (red line) over
6 weeks are displayed. Error
bars show standard deviation.
Scale bars show 10 lm
Fig. 6 Relationship between growth and initial volume of amyloid
plaques. The growth of amyloid plaques is quantiﬁed as the slope of a
linear ﬁt of the normalized volumes measured at each time point and
is shown as a function of the initial volume of plaques. a Data from
12 months old animals. Newborn plaques are shown in blue and pre-
existing plaques in red. b Data from 18 months old animals. No
newborn plaques were detected at that age. Pre-existing plaques are
shown in red
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123old mice [3]. However, we would further like to propose
the possibility that the high number of existing amyloid
plaques at this age and therefore the large total surface area
where newly formed Ab ﬁbrils can attach to existing pla-
ques could lead to a decelerated growth of each individual
plaque up to a degree that it is not detectable by two-
photon in vivo imaging anymore. It is furthermore inter-
esting to note that plaque size varied widely in 18 months
old animals (Fig. 2); yet we observed no newborn plaques
at that age (Fig. 6). Individual plaques, however, seemed
both to shrink and grow between measurements (Fig. 5).
While this suggests the exciting possibility that plaques
might be in a dynamic equilibrium, increasing measure-
ment errors with increasing plaque size (note the
heteroscedasticity in Figs. 3c, 4c) preclude us from making
a ﬁrm conclusion. Thus, our data show that both the
appropriate age and an appropriate observation period are
required in order to detect plaque growth. Furthermore, our
ﬁndings corroborate results which showed plaque growth
in different double-transgenic AD mouse models [2, 24].
In conclusion, we show that amyloid plaques do grow in
12 months old Tg2576 mice when amyloid pathology is in
the early stages [9]. Newborn amyloid plaques are initially
small in size and grow over the following weeks. After the
initial growth period, plaques continue to grow, albeit more
slowly, until plaque growth is not detectable anymore in
aged mice. These ﬁndings have important implications for
AD diagnosis and therapy. A recent study [12], for instance,
showed that in patients with mild cognitive impairment
(MCI), amyloid plaque load, as measured by
11C-Pittsburgh
compound B (PIB) retention in positron emission tomog-
raphy, increased over 5 years, while the regional cerebral
metabolic rate of glucose decreased. However, cognitive
function remained stable in these patients. Patients with
AD, in contrast, had higher PIB retention than patients with
MCI, which did not increase further over the observation
period, and showed a decline in the regional cerebral met-
abolic rate of glucose as well as in cognitive function. In
combination with our results, these data suggest that plaque
formation occurs early in the course of the disease, but
before a loss of cognitive function becomes apparent.
Therefore, drugs that target plaque formation should be
most effective early in the disease, when plaques are
growing. These results also suggest that a different mech-
anism may be responsible for the cognitive decline in
patients with manifest AD. Thus, an effort has to be made to
ﬁnd the mechanism of cognitive decline in the late disease
stages in order to tailor effective therapeutic strategies.
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